Healthcare
Live Price
Offline$5.28
+5.39% today
1Y Change
+15.44%
Window
Jun 23, 2025 → Jun 17, 2026
Coverage: 248 bars · Jun 23, 2025 → Jun 17, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
Sight Sciences, Inc. (SGHT) is a Healthcare stock with a market cap of $240.00M and listed on NASDAQ. The stock last traded around $5.28 and up 15.4% across the available one-year price window (Jun 23, 2025 → Jun 17, 2026). Baseline metrics include revenue growth of -3.1%, EPS growth of +28.2%, a dividend yield of 0.0%. What stands out right now is revenue -3.1%, EPS +28.2%, free cash flow -31.6% with operating margin -48.0% and ROIC -35.4%. Valuation is more restrained than many high-expectation growth names at price/sales 3.1. Overall, the current profile looks closer to a turnaround or cyclical reset than a generic broad-market placeholder. Stock Foundry combines SGHT price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Benchmark Comparison
Compare this ticker against a broad index, growth benchmark, or sector ETF using a shared 1Y normalization window.
SGHT
—
Normalized return
SPY
—
S&P 500
Excess Return
—
Relative to SPY
SGHT Max Drawdown
-61.88%
Trailing 1Y
SPY Max Drawdown
—
Trailing 1Y
Uses the longest available daily history for SGHT and SPY.
Financial profile
Profitability, balance sheet stamina, and cash efficiency drawn from the latest filings.
FY Revenue
$49.0M
-31.4% YoY
FY Net Income
-$63.0M
+27.0% YoY
Free Cash Flow
-$53.4M
+30.7% YoY
Revenue Growth
-3.1%
EPS Growth
+28.2%
Gross Margin
86.2%
Net Margin
-49.7%
Income statement
USD
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Revenue | 77M | 80M | 81M | 71M | 49M |
| Gross Profit | 67M | 68M | 69M | 59M | 40M |
| Operating Income | -37M | -51M | -57M | -84M | -51M |
| EBITDA | -37M | -46M | -49M | -80M | -57M |
| Net Income | -38M | -52M | -56M | -86M | -63M |
| EPS (Diluted) | — | — | — | — | — |
Balance sheet
USD
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Cash & Equivalents | 92M | 120M | 138M | 185M | 261M |
| Total Assets | 115M | 143M | 167M | 213M | 280M |
| Total Liabilities | 51M | 55M | 46M | 53M | 48M |
| Shareholder Equity | 64M | 88M | 120M | 160M | 232M |
| Total Debt | 41M | 40M | 35M | 35M | 34M |
| Net Debt | -51M | -80M | -103M | -150M | -226M |
Cash flow positioning
Latest Full Year
Operating Cash Flow
53M
+30.8% YoY
Capital Expenditures
813K
+16.2% YoY
Free Cash Flow
53M
+30.7% YoY
Key ratios
Gross Margin
86.2%
Operating Margin
-48.0%
Net Margin
-49.7%
ROE
-55.7%
Debt / Equity
0.64x
Next Step
Use the numbers to decide whether this is a growth candidate, a quality compounder, or just an interesting outlier.